Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
16885 | 566 | 31.5 | 82% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
3413 | 1150 | CILOSTAZOL//CLIN PHARMACOKINET PHARMACODYNAM METAB//AZECINES |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | CILOSTAZOL | Author keyword | 242 | 57% | 51% | 290 |
2 | CLIN PHARMACOKINET PHARMACODYNAM METAB | Address | 15 | 82% | 2% | 9 |
3 | CAS 73963 72 1 | Author keyword | 6 | 80% | 1% | 4 |
4 | TRIPLE ANTIPLATELET THERAPY | Author keyword | 6 | 58% | 1% | 7 |
5 | OPC 13013 | Author keyword | 4 | 75% | 1% | 3 |
6 | PHOSPHODIESTERASE 3 INHIBITOR | Author keyword | 3 | 33% | 1% | 8 |
7 | MED I EM TISSUE REGENERAT | Address | 3 | 15% | 3% | 16 |
8 | BULK PHARMACEUT CHEM | Address | 2 | 67% | 0% | 2 |
9 | CILOSTAZOL CLINICAL STUDIES | Author keyword | 2 | 67% | 0% | 2 |
10 | K 134 | Author keyword | 2 | 67% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | CILOSTAZOL | 242 | 57% | 51% | 290 | Search CILOSTAZOL | Search CILOSTAZOL |
2 | CAS 73963 72 1 | 6 | 80% | 1% | 4 | Search CAS+73963+72+1 | Search CAS+73963+72+1 |
3 | TRIPLE ANTIPLATELET THERAPY | 6 | 58% | 1% | 7 | Search TRIPLE+ANTIPLATELET+THERAPY | Search TRIPLE+ANTIPLATELET+THERAPY |
4 | OPC 13013 | 4 | 75% | 1% | 3 | Search OPC+13013 | Search OPC+13013 |
5 | PHOSPHODIESTERASE 3 INHIBITOR | 3 | 33% | 1% | 8 | Search PHOSPHODIESTERASE+3+INHIBITOR | Search PHOSPHODIESTERASE+3+INHIBITOR |
6 | CILOSTAZOL CLINICAL STUDIES | 2 | 67% | 0% | 2 | Search CILOSTAZOL++CLINICAL+STUDIES | Search CILOSTAZOL++CLINICAL+STUDIES |
7 | K 134 | 2 | 67% | 0% | 2 | Search K+134 | Search K+134 |
8 | AB INDEX | 1 | 50% | 0% | 2 | Search AB+INDEX | Search AB+INDEX |
9 | PERIPHERAL ARTERIAL OCCLUSION DISEASE PAOD | 1 | 100% | 0% | 2 | Search PERIPHERAL+ARTERIAL+OCCLUSION+DISEASE+PAOD | Search PERIPHERAL+ARTERIAL+OCCLUSION+DISEASE+PAOD |
10 | PLETAALR | 1 | 100% | 0% | 2 | Search PLETAALR | Search PLETAALR |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CHROMOSOME 10 PHOSPHORYLATION | 31 | 92% | 2% | 12 |
2 | EXPERIMENTAL THROMBOSIS | 20 | 59% | 4% | 22 |
3 | PHOSPHODIESTERASE INHIBITOR | 15 | 27% | 9% | 49 |
4 | TREATING INTERMITTENT CLAUDICATION | 12 | 75% | 2% | 9 |
5 | PHOSPHODIESTERASE TYPE 3 | 9 | 67% | 1% | 8 |
6 | CILOSTAZOL | 8 | 19% | 7% | 40 |
7 | AMP PHOSPHODIESTERASE INHIBITOR | 6 | 80% | 1% | 4 |
8 | RECEPTOR GAMMA TRANSCRIPTION | 6 | 80% | 1% | 4 |
9 | REDUCES LATE RESTENOSIS | 6 | 47% | 2% | 9 |
10 | III INHIBITOR | 5 | 42% | 2% | 10 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention | 2008 | 64 | 35 | 71% |
Efficacy of Cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials | 2009 | 46 | 43 | 60% |
The pharmacology of cilostazol | 2002 | 70 | 16 | 94% |
Cilostazol as a unique antithrombotic agent | 2003 | 100 | 132 | 56% |
Cilostazol (Pletal (R)): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake | 2001 | 92 | 70 | 64% |
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin | 2011 | 14 | 26 | 69% |
Long-term clinical efficacy and safety of adding cilostazol to dual antiplatelet therapy for patients undergoing PCI: a meta-analysis of randomized trials with adjusted indirect comparisons | 2014 | 3 | 45 | 44% |
CILOSTAZOL | 1993 | 50 | 22 | 77% |
Cilostazol for intermittent claudication | 2014 | 2 | 31 | 48% |
Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics | 1999 | 32 | 3 | 100% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | CLIN PHARMACOKINET PHARMACODYNAM METAB | 15 | 82% | 1.6% | 9 |
2 | MED I EM TISSUE REGENERAT | 3 | 15% | 2.8% | 16 |
3 | BULK PHARMACEUT CHEM | 2 | 67% | 0.4% | 2 |
4 | ADV PHARMACOL | 2 | 50% | 0.5% | 3 |
5 | CLIN PK PD METAB | 1 | 50% | 0.4% | 2 |
6 | GEFASSZENTRUM OBERRHEIN MANNHEIM SPEYER | 1 | 50% | 0.4% | 2 |
7 | NEW DRUG DISCOVERY 1 | 1 | 16% | 1.1% | 6 |
8 | EXECUT DEANS OFF | 1 | 40% | 0.4% | 2 |
9 | MERIDIAN STRUCT MED | 1 | 11% | 1.4% | 8 |
10 | PHARMACOL TEAM | 1 | 33% | 0.4% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000159004 | MOUSE LYMPHOID NEOPLASMA P 388//MOUSE MAMMARY CARCINOMA FM 3A//HUMAN HISTIOCYTIC LYMPHOMA U 937 |
2 | 0.0000105677 | IBUDILAST//CAS 50847 11 5//221 MIYAMA |
3 | 0.0000092325 | PROBUCOL//AGI 1067//SUCCINOBUCOL |
4 | 0.0000091361 | ANKLE BRACHIAL INDEX//INTERMITTENT CLAUDICATION//PERIPHERAL ARTERIAL DISEASE |
5 | 0.0000086544 | CLOPIDOGREL//PRASUGREL//TICAGRELOR |
6 | 0.0000080831 | CHRONIC CEREBRAL HYPOPERFUSION//PERMANENT OCCLUSION OF BILATERAL COMMON CAROTID ARTERIES//CEREBRAL HYPOPERFUSION |
7 | 0.0000062263 | VASCULAR SURGERY PROCEDURES//ARTERIOSCLEROSIS SURGERY//BOA TRIAL OFF |
8 | 0.0000056108 | ROLIPRAM//PDE4//PHOSPHODIESTERASE |
9 | 0.0000050751 | TRANSIENT ISCHEMIC ATTACK//ABCD2 SCORE//TIA |
10 | 0.0000048193 | I EM NEURODEGENERAT BRAIN//BERAPROST SODIUM//NEONATE INFANT PATHOL |